Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 30,000 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Day One Biopharmaceuticals Trading Down 2.7 %

DAWN opened at $12.81 on Friday. The firm’s 50 day moving average is $14.21 and its 200-day moving average is $14.04. Day One Biopharmaceuticals, Inc. has a 52-week low of $11.94 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period last year, the firm earned ($0.54) EPS. On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new stake in shares of Day One Biopharmaceuticals during the third quarter worth approximately $825,000. First Turn Management LLC bought a new position in Day One Biopharmaceuticals during the 3rd quarter valued at $13,204,000. Algert Global LLC grew its holdings in Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after acquiring an additional 50,990 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after purchasing an additional 1,250,000 shares during the last quarter. Finally, TimesSquare Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals by 8.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock valued at $25,460,000 after purchasing an additional 139,160 shares in the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.